Mylan’s Perrigo Play Could Be Under-Powered, Unappreciated
This article was originally published in The Tan Sheet
Executive Summary
Mylan learns it no longer is targeted by Teva in a $40 billion hostile takeover play and schedules a shareholder vote on acquiring all or part of Perrigo’s shares, while analysts expect the Rx generics firm will need to increase its offer to succeed.